PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Purpose: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-tim...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 4; pp. 895 - 907
Autores principales: Bodei, Lisa, Kidd, Mark S., Singh, Aviral, van der Zwan, Wouter A., Severi, Stefano, Drozdov, Ignat A., Malczewska, Anna, Baum, Richard P., Kwekkeboom, Dik J., Paganelli, Giovanni, Krenning, Eric P., Modlin, Irvin M.
Formato: Journal Article
Publicado: Springer Nature Apr2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142271066&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 142271066
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Apr2020
      vid: 47
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        142271066
        10.1007/s00259-019-04601-3
        142271066
      ppf: 895
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
      aug:
        au:
          Bodei, Lisa
          Kidd, Mark S.
          Singh, Aviral
          van der Zwan, Wouter A.
          Severi, Stefano
          Drozdov, Ignat A.
          Malczewska, Anna
          Baum, Richard P.
          Kwekkeboom, Dik J.
          Paganelli, Giovanni
          Krenning, Eric P.
          Modlin, Irvin M.
        affil: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, 10065, New York, NY, USA
      sug:
      ab: Purpose: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy; NETest monitors disease. We prospectively evaluated: (1) NETest as a surrogate biomarker for RECIST; (2) the correlation of NETest levels with PPQ prediction. Methods: Three independent 177Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n = 72; Bad-Berka, Germany: n = 44; Rotterdam, Netherlands: n = 41). Treatment response: RECIST1.1 (responder (stable, partial, and complete response) vs non-responder). Blood sampling: pre-PRRT, before each cycle and follow-up (2–12 months). PPQ (positive/negative) and NETest (0–100 score) by PCR. Stable < 40; progressive > 40). CgA (ELISA) as comparator. Samples de-identified, measurement and analyses blinded. Kaplan–Meier survival and standard statistics. Results: One hundred twenty-two of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p < 0.0001) decreased in RECIST "responders" (− 47 ± 3%); in "non-responders," it remained increased (+ 79 ± 19%) (p < 0.0005). NETest monitoring accuracy was 98% (119/122). Follow-up levels > 40 (progressive) vs stable (< 40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI, 0.02–0.07). PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p < 0.0001) decreased in PPQ-predicted responders (− 46 ± 3%) and remained elevated or increased in PPQ-predicted non-responders (+ 75 ± 19%). Follow-up NETest categories stable vs progressive significantly correlated with PPQ prediction and mPFS (not reached vs. 10 months; HR 0.06 (95%CI, 0.03–0.12). CgA did not reflect PRRT treatment: in RECIST responders decrease in 38% and in non-responders 56% (p = NS). Conclusions: PPQ predicts PRRT response in 97%. NETest accurately monitors PRRT response and is an effective surrogate marker of PRRT radiological response. NETest decrease identified responders and correlated (> 97%) with the pretreatment PPQ response predictor. CgA was non-informative.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N